Experiences with
Obinutuzumab359 public posts
Want to take advantage of all our features? Just log in!
or
Obinutuzumab not recommended for funding by NHS England
You can read more about obinutuzumab and this decision on our website: https://lupusuk.org.uk/obinutuzumab-not-recommended-for-funding-by-nhs-england/
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
for patients with chronic lymphocytic leukemia
https://www.healio.com/news/hematology-oncology/20240828/measurable-residual-disease-status-predicts-pfs-for-patients-with-chronic-lymphocytic-leukemia
[i]Rios-Olais and colleagues used data from prospective trials that evaluated targeted agents or obinutuzumab